Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 125, Issue 5, Pages 889-894Publisher
ELSEVIER SCIENCE INC
DOI: 10.1111/j.0022-202X.2005.23889.x
Keywords
clinical trial; cutaneous lupus erythematosus; discoid lupus erythematosus; outcome instrument; subacute lupus erythematosus
Categories
Funding
- NIAMS NIH HHS [2T32-AR-007465, T32 AR007465, K24 AR002207, K24-AR 02207] Funding Source: Medline
Ask authors/readers for more resources
We developed and validated a measurement instrument (CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate scores for damage and activity. A group of seven American Dermato-Rheumatologists and the American College of Rheumatology Response Criteria Committee on SLE (systemic lupus erythematosus) assessed content validity. After a preliminary session, we conducted standardized interviews with the raters and made slight changes to the instrument. The final instrument was evaluated by five dermatologists and six residents who scored nine patients to estimate inter- and intra-rater reliability in two sessions. Consultation with experts has established content validity of the instrument. Reliability studies demonstrated an intra-class correlation coefficient (ICC) for inter-rater reliability of 0.86 for the activity score (95% confidence interval (CI) = 0.73-0.99) and of 0.92 for the damage score (95% CI = 0.85-1.00). The Spearman's rho (Sp) for intra-rater reliability for the activity score was 0.96 (95% CI = 0.89 to 1.00) and for the damage score Sp was 0.99 (95% CI = 0.97-1.00). Clinical responsiveness needs to be evaluated in a prospective clinical trial, which is ongoing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available